The committee asked the company to submit a comparative analysis of late-stage immunogenicity data from both its Indian studies and an ongoing Russian study.

Over 91.15% of patients treated with PegIFN were found to be RT PCR negative by day 7 as compared to 78.90 per cent on the 'standard of care' arm; PegIFN reduced the duration for supplemental oxygen to 56 hours from 84 hours in moderate COVID-19 patients

Already the Russian Direct Investment Fund, the force behind the Russian vaccine, has signed deals with several Indian companies for the production and distribution of Sputnik V

The Pennsylvania-based biopharmaceutical firm is partnering with India's Bharat Biotech, a developer of the vaccine, to commercialize the shot in the United States

Pfizer wants to make vaccine in India; seeks assurance on faster clearance, export freedom Pfizer Inc has told the Indian government it wants to produce its coronavirus vaccine locally if assured of faster regulatory clearance and freedom on pricing and exports. The U.S. company pulled an application last month seeking emergency approval for its product in India after the drug regulator declined its request to skip a small local safety trial. That has kept its vaccine, developed with German...

The US company pulled an application last month seeking emergency approval for its product in India after the drug regulator declined its request to skip a small local safety trial. That has kept its vaccine, developed with Germany's BioNTech SE, out of one of the world's biggest drug markets

This is something very special and I see it myself because I'm on weekly teleconferences with our colleagues in India, you make a recommendation, and within days it's done and not only done, but it's done well and with incredible rigor and thought and creativity, Dr Hotez said

Government data shows that only 10% of about 12.6 million people immunised in India have taken the COVAXIN shot, which was found to be 81% effective in an interim analysis of the late-stage trial, its developer Bharat Biotech said

\"The UK has ordered 100 million doses of AstraZeneca's COVID-19 vaccine, of which 10 million doses will come from the Serum Institute of India,\" a UK government spokesperson told Reuters

Some 500,000 doses made by SII, the world's largest vaccine producer, are set to arrive in Canada on Wednesday, a surprise boost for Canada's lagging vaccination drive

The government, in this phase, will vaccinate people over 60 and individuals over 45 with comorbidities to rein in the rising number of more infectious virus strains leading to a spurt in COVID-19 cases in some states

While the prices of four categories of medical devices - coronary stents, drug-eluting stents, condoms, and intrauterine devices - are already fixed by NPPA, the prices of the rest are fixed by the manufacturers themselves

Just the two shots have been used in what India calls the world's biggest immunisation programme to cover 300 million people by August, starting with healthcare and other workers to reach the elderly and those with existing conditions by March

External Affairs Minister S Jaishankar said some poor countries are being supplied the vaccine on a grant basis, while some nations wanted it on par with the price that the Indian government pays to the vaccine makers

Coronavirus vaccine: Pfizer was the first pharmaceutical company to seek EUA from Drugs Controller General of India (DCGI) after its vaccine was approved in the UK and Bahrain

The study published in 'PrePrints with the The Lancet' reveals that administration of the Oxford-AstraZeneca vaccine has 'substantially reduced' transmission of the virus

Serum Institute of India CEO Adar Poonawalla told Reuters that the doses destined for Saudi Arabia would be shipped in a week or 10 days

There were no serious side effects in the participants enrolled for the phase 1 trial of Covaxin, according to the results published in The Lancet

Pfizer is yet to submit additional data sought by India authorities regarding its COVID-19 vaccine for granting emergency use approval to it; the company has missed last three SEC meetings too

World Health Organization (WHO) chief scientist, Dr. Soumya Swaminathan's comments come in the backdrop of several Indian vaccine makers and medical experts complaining about the confusing manner in which DCGI has granted emergency use approvals for COVID-19 vaccines in India